{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:12:14Z","timestamp":1791162734753,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1053\/j.gastro.2003.10.047","type":"journal-article","created":{"date-parts":[[2003,12,30]],"date-time":"2003-12-30T18:41:09Z","timestamp":1072809669000},"page":"19-31","source":"Crossref","is-referenced-by-count":718,"title":["The safety profile of infliximab in patients with Crohn\u2019s disease: The Mayo Clinic experience in 500 patients"],"prefix":"10.1053","volume":"126","author":[{"given":"Jean-Frederic","family":"Colombel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Tremaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence J.","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.Scott","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy D.","family":"Schleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Zinsmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2003.10.047_BIB1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2003.10.047_BIB2","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2003.10.047_BIB3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"2002","key":"10.1053\/j.gastro.2003.10.047_BIB4","first-page":"A81","article-title":"Long-term treatment of fistulizing Crohn\u2019s disease","volume":"122","author":"Sands","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2003.10.047_BIB5","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1111\/j.1572-0241.2000.03363.x","article-title":"Infliximab in Crohn\u2019s disease","volume":"95","author":"Cohen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2003.10.047_BIB6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","article-title":"Infliximab for Crohn\u2019s disease in clinical practice at the Mayo Clinic","volume":"96","author":"Ricart","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2003.10.047_BIB7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00054725-200203000-00002","article-title":"Infliximab treatment for Crohn\u2019s disease","volume":"8","author":"Hommes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2003.10.047_BIB8","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn\u2019s disease","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2003.10.047_BIB9","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0016-5085(98)70421-4","article-title":"Crohn\u2019s disease in Olmsted County, Minnesota, 1940\u20131993","volume":"114","author":"Loftus","year":"1998","journal-title":"Gastroenterology"},{"issue":"suppl","key":"10.1053\/j.gastro.2003.10.047_BIB10","first-page":"A731","article-title":"Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2\u20134 year interval without treatment","volume":"116","author":"Hanauer","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2003.10.047_BIB11","series-title":"Remicade (infliximab) for IV injection. Package Insert","year":"2002"},{"key":"10.1053\/j.gastro.2003.10.047_BIB12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2003.10.047_BIB13","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs","volume":"40","author":"Begaud","year":"1985","journal-title":"Therapie"},{"key":"10.1053\/j.gastro.2003.10.047_BIB14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2003.10.047_BIB15","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2003.10.047_BIB16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00054725-200205000-00005","article-title":"Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion","volume":"8","author":"Riegert-Johnson","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2003.10.047_BIB17","doi-asserted-by":"crossref","DOI":"10.1097\/00054725-200401000-00004","article-title":"Demyelination during anti-tumor necrosis factor therapy with infliximab for Crohn\u2019s disease","author":"Thomas","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2003.10.047_BIB18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"suppl C","key":"10.1053\/j.gastro.2003.10.047_BIB19","doi-asserted-by":"crossref","first-page":"29C","DOI":"10.1155\/2000\/698523","article-title":"Long term safety of infliximab","volume":"14","author":"Schaible","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.gastro.2003.10.047_BIB20","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2003.10.047_BIB21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2003.10.047_BIB22","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2003.10.047_BIB23","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2003.10.047_BIB24","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/j.1572-0241.2000.03366.x","article-title":"Clinical experience with infliximab therapy in 100 patients with Crohn\u2019s disease","volume":"95","author":"Farrell","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2003.10.047_BIB25","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1111\/j.1572-0241.2002.07093.x","article-title":"Infliximab in the treatment of Crohn\u2019s disease","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2003.10.047_BIB26","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1111\/j.1572-0241.2000.02349.x","article-title":"Severe anaphylactic reaction to infliximab","volume":"95","author":"Soykan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2003.10.047_BIB27","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1023\/A:1015326715456","article-title":"Anaphylaxis-like reaction to infliximab in a patient with Crohn\u2019s disease","volume":"47","author":"O\u2019Connor","year":"2002","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2003.10.047_BIB28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00054725-200102000-00005","article-title":"Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn\u2019s disease patients with prior anaphylactic reaction","volume":"7","author":"Puchner","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2003.10.047_BIB29","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1572-0241.2002.05784.x","article-title":"Infliximab retreatment in adults and children with Crohn\u2019s disease","volume":"97","author":"Kugathasan","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2003.10.047_BIB30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn\u2019s disease","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2003.10.047_BIB31","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/41.8.951","article-title":"Pneumocystis carinii pneumonia following a second infusion of infliximab","volume":"41","author":"Tai","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.gastro.2003.10.047_BIB32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-9343(01)00945-7","article-title":"Reactivation of histoplasmosis after treatment with infliximab","volume":"112","author":"Nakelchik","year":"2002","journal-title":"Am J Med"},{"key":"10.1053\/j.gastro.2003.10.047_BIB33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00005176-200204000-00018","article-title":"Listeria meningitis after treatment with infliximab","volume":"34","author":"Kamath","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2003.10.047_BIB34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1572-0241.2000.01872.x","article-title":"Does administration of infliximab increase susceptibility to listeriosis?","volume":"95","author":"Morelli","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2003.10.047_BIB35","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/art.10374","article-title":"Anti-tumor necrosis factor therapy and Listeria monocytogenes infection","volume":"46","author":"Gluck","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2003.10.047_BIB36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","article-title":"Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Warris","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2003.10.047_BIB37","doi-asserted-by":"crossref","first-page":"41701","DOI":"10.1074\/jbc.M206473200","article-title":"Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation","volume":"277","author":"Gutierrez","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1053\/j.gastro.2003.10.047_BIB38","series-title":"Remicade (infliximab) for IV injection. Package Insert","year":"2003"},{"key":"10.1053\/j.gastro.2003.10.047_BIB39","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO;2-R","article-title":"Extracolonic malignancies in inflammatory bowel disease","volume":"67","author":"Ekbom","year":"1991","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2003.10.047_BIB40","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/0016-5085(94)90807-9","article-title":"Crohn\u2019s disease and cancer","volume":"107","author":"Persson","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2003.10.047_BIB41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/gut.42.2.175","article-title":"General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease","volume":"42","author":"Palli","year":"1998","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2003.10.047_BIB42","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2003.10.047_BIB43","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/gast.1996.v110.pm8613037","article-title":"Survival and cause-specific mortality in inflammatory bowel disease","volume":"110","author":"Persson","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2003.10.047_BIB44","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/gast.2002.33632","article-title":"Mortality and causes of death in Crohn\u2019s disease","volume":"122","author":"Jess","year":"2002","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508503017153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508503017153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T21:52:31Z","timestamp":1550267551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508503017153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0016508503017153"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2003.10.047","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}